Matches in SemOpenAlex for { <https://semopenalex.org/work/W181996218> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W181996218 endingPage "5" @default.
- W181996218 startingPage "691" @default.
- W181996218 abstract "Gemcitabine is widely used as a first-line therapy for biliary tract cancer (BTC). However, few studies have been conducted to analyze second- line therapies.From 33 patients who had been administered gemcitabine following resection between May 2005 and August 2007, we retrospectively analyzed the safety and efficacy of S-1 in 11 cases who received S-1 as second-line therapy due to recurrence or relapse of the primary disease.Among the adverse events (AEs) observed during S-1 administration, the most common was a decrease in the concentration of hemoglobin, followed by thrombocytopenia. No Grade 4 AEs or worse were detected. In addition, the AEs and their respective severity strongly resembled those of gemcitabine used as a first-line therapy. There were 7 cases that could be evaluated according to RECIST criteria, of which 1 was considered in the partial response and 3 as stable disease. The medians of time to progression after S-1 administration and survival after S-1 administration were 5.6 months and 31 months, respectively.S-1 could be taken safely as a second-line therapy without provoking severe AEs. By preventing the cessation of S-1 administration due to its AEs, more continued S-1 administration could lead to a better prognosis for BTC." @default.
- W181996218 created "2016-06-24" @default.
- W181996218 creator A5000662848 @default.
- W181996218 creator A5003288023 @default.
- W181996218 creator A5007072632 @default.
- W181996218 creator A5011710526 @default.
- W181996218 creator A5024700700 @default.
- W181996218 creator A5026201618 @default.
- W181996218 creator A5032460845 @default.
- W181996218 creator A5035267287 @default.
- W181996218 creator A5039507236 @default.
- W181996218 creator A5062435576 @default.
- W181996218 creator A5063504063 @default.
- W181996218 creator A5080903348 @default.
- W181996218 creator A5086139902 @default.
- W181996218 date "2012-05-01" @default.
- W181996218 modified "2023-09-27" @default.
- W181996218 title "An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer." @default.
- W181996218 doi "https://doi.org/10.5754/hge11530" @default.
- W181996218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22469710" @default.
- W181996218 hasPublicationYear "2012" @default.
- W181996218 type Work @default.
- W181996218 sameAs 181996218 @default.
- W181996218 citedByCount "4" @default.
- W181996218 countsByYear W1819962182013 @default.
- W181996218 countsByYear W1819962182016 @default.
- W181996218 countsByYear W1819962182022 @default.
- W181996218 crossrefType "journal-article" @default.
- W181996218 hasAuthorship W181996218A5000662848 @default.
- W181996218 hasAuthorship W181996218A5003288023 @default.
- W181996218 hasAuthorship W181996218A5007072632 @default.
- W181996218 hasAuthorship W181996218A5011710526 @default.
- W181996218 hasAuthorship W181996218A5024700700 @default.
- W181996218 hasAuthorship W181996218A5026201618 @default.
- W181996218 hasAuthorship W181996218A5032460845 @default.
- W181996218 hasAuthorship W181996218A5035267287 @default.
- W181996218 hasAuthorship W181996218A5039507236 @default.
- W181996218 hasAuthorship W181996218A5062435576 @default.
- W181996218 hasAuthorship W181996218A5063504063 @default.
- W181996218 hasAuthorship W181996218A5080903348 @default.
- W181996218 hasAuthorship W181996218A5086139902 @default.
- W181996218 hasConcept C121332964 @default.
- W181996218 hasConcept C121608353 @default.
- W181996218 hasConcept C126322002 @default.
- W181996218 hasConcept C141071460 @default.
- W181996218 hasConcept C142424586 @default.
- W181996218 hasConcept C143998085 @default.
- W181996218 hasConcept C197934379 @default.
- W181996218 hasConcept C2780258809 @default.
- W181996218 hasConcept C3017919176 @default.
- W181996218 hasConcept C3018840467 @default.
- W181996218 hasConcept C3019894029 @default.
- W181996218 hasConcept C71924100 @default.
- W181996218 hasConcept C87355193 @default.
- W181996218 hasConcept C90924648 @default.
- W181996218 hasConceptScore W181996218C121332964 @default.
- W181996218 hasConceptScore W181996218C121608353 @default.
- W181996218 hasConceptScore W181996218C126322002 @default.
- W181996218 hasConceptScore W181996218C141071460 @default.
- W181996218 hasConceptScore W181996218C142424586 @default.
- W181996218 hasConceptScore W181996218C143998085 @default.
- W181996218 hasConceptScore W181996218C197934379 @default.
- W181996218 hasConceptScore W181996218C2780258809 @default.
- W181996218 hasConceptScore W181996218C3017919176 @default.
- W181996218 hasConceptScore W181996218C3018840467 @default.
- W181996218 hasConceptScore W181996218C3019894029 @default.
- W181996218 hasConceptScore W181996218C71924100 @default.
- W181996218 hasConceptScore W181996218C87355193 @default.
- W181996218 hasConceptScore W181996218C90924648 @default.
- W181996218 hasIssue "115" @default.
- W181996218 hasLocation W1819962181 @default.
- W181996218 hasOpenAccess W181996218 @default.
- W181996218 hasPrimaryLocation W1819962181 @default.
- W181996218 hasRelatedWork W181996218 @default.
- W181996218 hasRelatedWork W2009590010 @default.
- W181996218 hasRelatedWork W2043917781 @default.
- W181996218 hasRelatedWork W2045231641 @default.
- W181996218 hasRelatedWork W2049822713 @default.
- W181996218 hasRelatedWork W2167479710 @default.
- W181996218 hasRelatedWork W2588308010 @default.
- W181996218 hasRelatedWork W2793033650 @default.
- W181996218 hasRelatedWork W2996980037 @default.
- W181996218 hasRelatedWork W3090680712 @default.
- W181996218 hasVolume "59" @default.
- W181996218 isParatext "false" @default.
- W181996218 isRetracted "false" @default.
- W181996218 magId "181996218" @default.
- W181996218 workType "article" @default.